|
|
Post by hammer on Nov 3, 2015 7:58:31 GMT -5
Lakars, Seems like a lot of cloak and daggar stuff. It appears to me you are of the assumption that Nov. 6th Sanofi will in some way shape or form exhibit support for Afrezza in their reorganized diabetic platform. This is the flop card. The two wildcards in your assumption, is that MNKD is very close to licensing deals for TWO TS applications hence the meeting of the board? In addition you have promoted 2 more cards to finish the hand. I would infer these to be approval/marketing in another territory (Israel) and qualification of SNY insulin as secondary API in Afrezza.
Yes, No or close...based solely upon D/d and opinion? |
|
|
|
Post by biotec on Nov 3, 2015 8:38:56 GMT -5
Lakars, Seems like a lot of cloak and daggar stuff. It appears to me you are of the assumption that Nov. 6th Sanofi will in some way shape or form exhibit support for Afrezza in their reorganized diabetic platform. This is the flop card. The two wildcards in your assumption, is that MNKD is very close to licensing deals for TWO TS applications hence the meeting of the board? In addition you have promoted 2 more cards to finish the hand. I would infer these to be approval/marketing in another territory (Israel) and qualification of SNY insulin as secondary API in Afrezza.
Yes, No or close...based solely upon D/d and opinion? Why would anyone take investing speculation from a small retail investor (Lakars) Who claims to have inside information? I think this is a bunch of hot air. Being teased like a kid in middle school over illegal information is a waste of my time. |
|
|
|
Post by hammer on Nov 3, 2015 9:15:32 GMT -5
Lakars, Seems like a lot of cloak and daggar stuff. It appears to me you are of the assumption that Nov. 6th Sanofi will in some way shape or form exhibit support for Afrezza in their reorganized diabetic platform. This is the flop card. The two wildcards in your assumption, is that MNKD is very close to licensing deals for TWO TS applications hence the meeting of the board? In addition you have promoted 2 more cards to finish the hand. I would infer these to be approval/marketing in another territory (Israel) and qualification of SNY insulin as secondary API in Afrezza.
Yes, No or close...based solely upon D/d and opinion? Why would anyone take investing speculation from a small retail investor (Lakars) Who claims to have inside information? I think this is a bunch of hot air. Being teased like a kid in middle school over illegal information is a waste of my time. Biotec, Its not about taking advice from anybody, whether its a star investor or a lowly retail investor. For me its a matter of confirming my D&D with others who apparently also do their own. This board among others would be empty if we did not build assumptions/opinions upon other's opinion whether like minded or not. No man is an island, entire of itself.
|
|
|
|
Post by lakers on Nov 3, 2015 11:24:42 GMT -5
Lakars, Seems like a lot of cloak and daggar stuff. It appears to me you are of the assumption that Nov. 6th Sanofi will in some way shape or form exhibit support for Afrezza in their reorganized diabetic platform. This is the flop card. The two wildcards in your assumption, is that MNKD is very close to licensing deals for TWO TS applications hence the meeting of the board? In addition you have promoted 2 more cards to finish the hand. I would infer these to be approval/marketing in another territory (Israel) and qualification of SNY insulin as secondary API in Afrezza.
Yes, No or close...based solely upon D/d and opinion? You and MNholdem are some of the savviest, highly intelligent. Are you a PharmD? Or in biotech field? I have seen many Outstanding opinions from you. 50% close IMHO. A new indicator will also be decided - right on the clock. I'd like to see MS, RA. It's up to Al to decide how he wants to unlock SH value. He still calls all the shots and is the de facto proprietor. IMHO, jpg is a PCP. So is Ashiwi. Docafrezza is also a PCP. But he doesn't post here. Who else is MD on this PB? Don't think any Endo poster here. |
|
|
|
Post by rrtzmd on Nov 3, 2015 11:42:51 GMT -5
My own overall response to this thread is, "who cares?" How often do BOD meetings result in anything for any company? BODs overall seem to be a useless, wasteful requirement of incorporation. Off the top of my head, I can't think of a company where the BOD actually did something useful that resulted in a benefit to shareholders.
|
|
|
|
Post by docfrezza on Nov 3, 2015 11:43:04 GMT -5
FACTS:
docfrezza is a pcp
he does post here
and reads most but not all of what is written here |
|
|
|
Post by lakers on Nov 3, 2015 11:49:10 GMT -5
FACTS:
docfrezza is a pcp
he does post here
and reads most but not all of what is written here You are As new as I am. Your info is highly accurate. Hope you post more often. You are a PCP indeed. |
|
|
|
Post by mnholdem on Nov 3, 2015 11:50:11 GMT -5
Thank you, lakers, for the flattery. I too, think that this thread has been pretty much cloak and dagger reading material.
Time to lock it.
|
|
